Your browser is no longer supported. Please, upgrade your browser.
GSK GlaxoSmithKline plc daily Stock Chart
GlaxoSmithKline plc
Index- P/E6.35 EPS (ttm)6.65 Insider Own- Shs Outstand2.44B Perf Week-2.87%
Market Cap103.23B Forward P/E15.68 EPS next Y2.70 Insider Trans- Shs Float2.39B Perf Month-4.02%
Income16.03B PEG0.83 EPS next Q0.25 Inst Own10.10% Short Float0.17% Perf Quarter-8.36%
Sales36.25B P/S2.85 EPS this Y-48.90% Inst Trans0.59% Short Ratio1.11 Perf Half Y1.63%
Book/sh4.88 P/B8.66 EPS next Y13.47% ROA22.90% Target Price45.67 Perf Year-17.82%
Cash/sh6.72 P/C6.29 EPS next 5Y7.70% ROE178.10% 52W Range40.13 - 51.88 Perf YTD1.63%
Dividend2.31 P/FCF- EPS past 5Y-12.20% ROI15.00% 52W High-18.54% Beta0.64
Dividend %5.47% Quick Ratio1.00 Sales past 5Y-4.10% Gross Margin68.70% 52W Low5.31% ATR0.56
Employees98702 Current Ratio1.30 Sales Q/Q0.20% Oper. Margin21.50% RSI (14)41.59 Volatility1.29% 1.01%
OptionableYes Debt/Eq2.48 EPS Q/Q1110.90% Profit Margin44.40% Rel Volume0.56 Prev Close42.14
ShortableYes LT Debt/Eq2.05 EarningsJul 29 Payout37.70% Avg Volume3.77M Price42.26
Recom2.80 SMA20-1.21% SMA50-4.25% SMA200-4.73% Volume2,103,696 Change0.28%
Jun-26-15Upgrade Liberum Sell → Hold
Jun-04-15Downgrade Morgan Stanley Overweight → Equal-Weight
May-20-15Resumed Citigroup Neutral
Apr-15-15Initiated Societe Generale Sell
Feb-19-15Reiterated Argus Buy $55 → $52
Aug-08-14Reiterated Argus Buy $65 → $55
Apr-23-14Upgrade Argus Hold → Buy
May-28-13Upgrade Deutsche Bank Hold → Buy
Jan-11-11Upgrade Jefferies Hold → Buy
Jun-02-10Upgrade Jefferies Hold → Buy
Feb-16-10Upgrade JP Morgan Underweight → Neutral $26
Jan-13-10Downgrade Credit Suisse Outperform → Underperform
Nov-24-09Initiated Leerink Swann Mkt Perform
Nov-16-09Initiated Deutsche Securities Hold
Nov-12-09Initiated Barclays Capital Equal Weight
Oct-23-09Downgrade Jefferies & Co Buy → Hold
Mar-17-09Initiated Credit Suisse Outperform
Jan-26-09Initiated Jefferies & Co Buy
Nov-14-08Downgrade UBS Buy → Neutral
Apr-18-08Downgrade JP Morgan Neutral → Underweight
Jul-02-15 09:00AM  GSK's Viiv arm agrees China tie-up to produce HIV drugs at Financial Times
03:00AM  ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries PR Newswire
Jul-01-15 02:15PM  GlaxoSmithKline to open $95M nonprofit cell research center in Seattle at
08:02AM  Can Hepatitis B Be A Blockbuster Bug? at Investor's Business Daily
05:22AM  Drug companies grilled over Aust pricing AAP
Jun-30-15 09:52PM  Inquiry asks about drug price 'rip-off' AAP
05:31PM  Big pharma to be grilled on tax avoidance AAP
05:26PM  Pharma giant GlaxoSmithKline reveals $175K paid to hundreds of Triangle doctors at
01:47PM  Glaxo Paid Doctors $15 Million Before Pledge to End Fees in 2016 at Bloomberg
Jun-29-15 09:43AM  3 Reasons I Have Little Confidence in GlaxoSmithKline's Dividend at Motley Fool
Jun-26-15 06:02PM  Dow 30 Stock Roundup: Nike Beats Estimates, Verizon Closes AOL Buy - Analyst Blog
07:48AM  GlaxoSmithKline upgraded by Liberum
Jun-25-15 04:35PM  Glaxo, Pfizer Meningitis B Vaccines Get ACIP's Category B - Analyst Blog
11:16AM  Parexel to cut 850 jobs; Durham impact not immediately known at
Jun-24-15 01:33PM  Eurozone Business Activity Is at Its Highest Level in 4 Years
01:32PM  U.S. CDC committee recommends physicians make individual decisions on the use of meningococcal group B vaccines PR Newswire
Jun-23-15 04:40PM  Pfizer to Buy Two Meningitis Vaccines from Glaxo for $130M - Analyst Blog
03:51PM  GSK Vaccinates Pfizer to Gain Novartis - Video Blog
Jun-22-15 05:41PM  Pfizer to buy two vaccines from Glaxo AAP
09:28AM  GlaxoSmithKline (GSK) Stock Gains Following Meningitis Vaccines Sale to Pfizer at TheStreet
08:35AM  Pfizer to Acquire Two Meningitis Vaccines at The Wall Street Journal
07:45AM  GSK sells two vaccines to Pfizer to ease competition concerns Reuters
05:40AM  Gardasil-9 Effectively Stops 90 Percent Of Cancers Caused By HPV In Girls and Boys at Forbes
Jun-18-15 11:02PM  British Investigator Says Chinese Officials Tried to Force Confession at The Wall Street Journal
02:21PM  U.K. Investigator Says Chinese Officials Tried to Force Confession at The Wall Street Journal
09:37AM  Chardan: Sell Axovant Sciences, RVT-101 Market Pricing Is 'Highly Irrational'
08:24AM  Slow Sales Uptake For Brintellix Show The Challenges Facing New Depression Drugs at Forbes
06:30AM  UK investigator says Chinese officials mistreated him to get GSK confession Reuters
Jun-17-15 06:00PM  Cramer: How to play today's Fed meeting
02:10PM  GlaxoSmithKline dropping $95M to create research institute at
08:01AM  Photographer Documents Deadly Brain Infection As CDC Considers Vaccine at Forbes
Jun-16-15 10:00PM  GlaxoSmithKline, Searching For Hit Drugs, Pours $95M Into The 'Living Genome' at Forbes
03:19PM  Biotech Bonanza Shouldn't Bother GSK -- Overheard at The Wall Street Journal
12:12PM  A 29-year-old former Wall Streeter bought an Alzheimer's drug that failed clinical trials and now his company is worth $3 billion
12:08PM  Biotech Bonanza Shouldn't Bother GSK at The Wall Street Journal
Jun-15-15 11:38AM  Eurozone: Industrial Production Is Up, but Exports Need to Catch Up
08:23AM  Quartet of GSK cast-off drugs soar to a combined value of $5bn at Financial Times
Jun-14-15 07:07PM  Guru Stocks at 52-Week Lows: XOM, WMT, PG, CVX, GSK
Jun-12-15 03:18PM  Bets ahead of experimental Alzheimer's drug
11:31AM  Is the Axovant Stock Sale a Harbinger of a Biotech Bubble? at The Wall Street Journal
08:03AM  How bubbles are blown: Biotech edition (Exhibit III)
Jun-11-15 07:32PM  Dementia drug developer Axovant climbs after $315M IPO
06:23PM  Biggest biotech IPO ever-and the CEO is 29! at CNBC
06:15PM  Axovant CEO: Focused on treating Alzheimer's
04:58PM  Axovant Sciences Sets 20-Year Record For Biotech IPOs at Investor's Business Daily
12:58PM  Isis, Biogen Rare-Disease Drug Aids Infant Survival at Investor's Business Daily
12:44PM  Fresh fears of biotech bubble as Axovant soars on NYSE debut at Financial Times
Jun-10-15 01:45PM  Sainsbury's guidance buoys UK retailers at Financial Times
11:19AM  Hedge Funds Buying Biotech IPO Operated By Ex-Fund Manager
05:51AM  Glaxo Investigator Humphrey Released Early From Chinese Prison at Bloomberg
Jun-09-15 07:53PM  Biotechs Latest Miracle Drug at The Wall Street Journal
07:15PM  Cervical cancer vaccine might work after just 1 shot, not 3
05:32AM  GSK investigator Humphrey freed from China jail at Financial Times
Jun-08-15 02:34PM  Inside the Hedge Fund Club Pitching a New Alzheimer's Drug IPO at TheStreet
Jun-03-15 03:32PM  Perrigo to Buy OTC Brands from GlaxoSmithKline in Europe - Analyst Blog
01:30PM  American Pharoahs monster deal
Jun-02-15 04:45PM  Perrigo Buys GlaxoSmithKline, Novartis Consumer Medicines at TheStreet
01:08PM  Will Perrigo's Glaxo Buy Make It Too Pricey? at Investor's Business Daily
May-29-15 10:41AM  GlaxoSmithKline LLC -- Moody's changes outlook on GSK's A2 issuer rating to negative at Moody's
09:50AM  Veeva Beats Q1 Earnings on Strong Revenues, Stock Down - Analyst Blog
05:53AM  Glaxo Bulls Awaken With Calls as Pfizer Merger Chatter Escalates at Bloomberg
05:53AM  Glaxo Bulls Awaken as Pfizer Merger Chatter Escalates
May-26-15 09:00AM  ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV PR Newswire
May-24-15 07:19PM  Innovation and scale fuel growth in Big Pharma at Financial Times
06:21PM  Investors prepared to give Sir Andrew Witty time to revive GSK at Financial Times
May-22-15 07:58PM  Would Pfizer Buying GlaxoSmithKline Make Sense? at Investopedia
08:11AM  Who are Gilead Sciences' (GILD) main competitors? at Investopedia
May-21-15 05:35PM  All Eyes on Pfizer as Shareholders Await the Mega-Deal: Real M&A at Bloomberg
12:45PM  How a "PfizerKline" would impact the Triangle at
May-20-15 05:25PM  $5.6B In Fines Against Major Banks Seems Like A Lot. Here's Why It Won't Deter Corporate Crime. at Forbes
01:50PM  GSK unmoved by broker talk of takeover at Financial Times
08:54AM  Pfizer Would Benefit From Glaxo Takeover, Deutsche Bank Says at Bloomberg
May-19-15 09:00AM  New Study Shows Inner-City Asthma Care Program Reduces Student Absenteeism by up to 20 Percent PR Newswire
May-15-15 06:00PM  Cramer: Next week jam-packed with retail earnings
04:21PM  Healthcare Winners and Losers: May 15, 2015
May-14-15 04:55PM  Emergent BioSolutions, Glaxo Initiate Ebola Vaccine Study - Analyst Blog
12:57PM  FTSE 100 finds its footing as Draghi backs eurozone stimulus at MarketWatch
07:13AM  Is Sir Andrew Witty The Person To Lead A Major Pharmaceutical Company? at Forbes
May-12-15 08:31AM  GSK's Curious Oncology Research Position -- A Recipe For Failure? at Forbes
May-11-15 02:34PM  CNBC update: Ukraine warning
01:14PM  GlaxoSmithKline chief questions rivals' chasing M&A deals at Financial Times
01:13PM  GlaxoSmithKline: Out of step at Financial Times
01:03PM  HIV Cure Is Goal of Glaxo-UNC Chapel Hill Partnership at The Wall Street Journal
May-10-15 10:06PM  Partnership Takes Aim at Curing HIV/AIDS at The Wall Street Journal
10:00PM  Hunt for AIDS cure accelerates as GSK and U.S. experts link up
11:31AM  GlaxoSmithKline chief seeks immunity from sector's herd mentality at Financial Times
May-08-15 12:47PM  Week in Review, May 9 at Financial Times
May-07-15 03:10PM  Glaxo's (GSK) Q1 Earnings Fall Y/Y; Gives Five-Year View - Analyst Blog
12:45PM  Outgoing chairman defends record at GSK at Financial Times
11:50AM  Theravance (THRX) Reports Wider-than-Expected Q1 Loss - Analyst Blog
11:48AM  New GSK chairman backs CEO Witty to stay at helm
08:07AM  GlaxoSmithKline plc announces Board and Committee changes at noodls
03:50AM  U.K. Stocks Fall as Voting Begins, With GlaxoSmithKline Dropping at Bloomberg
May-06-15 10:25PM  China Said to Probe Ex-Official Who Oversaw Clinical Drug Trials at Bloomberg
07:54PM  PRESS DIGEST- British Business - May 7 Reuters
07:03PM  United Kingdom votes in most unpredictable election in decades Reuters
06:08PM  Today's Top 5 Stock Picks: Undervalued Large-Caps at
04:41PM  Drug developer Adaptimmune skids after IPO raises $191M
01:33PM  GSK's Sturdy Strategy Leaves Investors Waiting at The Wall Street Journal
01:17PM  GSK's new strategy
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas. The company's wellness products include Panadol and Panadol Cold & Flu for headache, joint pain, fever, and cold symptoms; ENO and Tums that are immediate relief antacids; and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to smoking reduction and cessation. Its oral health products comprise Sensodyne to treat and prevent dental sensitivity and acid erosion; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; and Aquafresh for the prevention of caries, gum disease, and bad breath. The company's nutrition products include Horlicks, a nutritional beverages and food; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, as well as Zovirax and Abreva to treat and prevent the onset of cold sores. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GLAXOSMITHKLINE PLC10% OwnerMay 11Buy14.00365,1065,111,484365,106May 13 12:36 PM
GLAXOSMITHKLINE PLC10% OwnerMar 02Buy18.0692,6741,673,69231,673,853Mar 02 03:45 PM
GLAXOSMITHKLINE PLC10% OwnerAug 11Buy22.66172,6513,912,27230,748,723Aug 11 04:55 PM